The INCORRECT Statement is C
Statement C is incorrect: Acute colonic pseudo-obstruction (Ogilvie syndrome) is NOT always accompanied by complete cessation of bowel movements and flatus. In fact, the clinical vignette itself demonstrates this—the patient continues to pass flatus and have bowel movements despite having Ogilvie syndrome.
Why Statement C is Wrong
The evidence clearly shows that Ogilvie syndrome can present with continued passage of flatus and stool. While mechanical large bowel obstruction typically presents with absence of flatus (90%) and feces (80.6%), pseudo-obstruction represents a functional rather than mechanical process 1. The patient described has ongoing flatus and bowel movements, which is entirely consistent with Ogilvie syndrome and actually helps distinguish it from true mechanical obstruction.
Why the Other Statements Are Correct
Statement A: Rule out electrolyte disturbances ✓
Electrolyte imbalances are critical precipitants of Ogilvie syndrome and must be corrected. Laboratory evaluation should focus on electrolyte disturbances, particularly hypokalemia, which can impair colonic motility and precipitate pseudo-obstruction 2. Correction of severe hypokalemia alone has been shown to resolve colonic pseudo-obstruction within 48 hours 2.
Statement B: Discontinue opioids and anticholinergics ✓
These medications directly contribute to colonic dysmotility. In this patient with Parkinson's disease, anticholinergic medications used for symptom management can significantly worsen colonic pseudo-obstruction 3, 4. Opioids similarly impair colonic motility and should be discontinued when possible.
Statement D: Cecal diameter >12 cm carries increased risk of perforation ✓
This is a critical threshold for intervention. When cecal diameter exceeds 12 cm, the risk of ischemia and perforation increases substantially, warranting more aggressive management including neostigmine or decompressive colonoscopy.
Statement E: Neostigmine administration criteria ✓
Neostigmine should be administered if conservative therapy fails after 48 hours OR if colonic diameter exceeds 12 cm. Multiple case reports demonstrate the efficacy and safety of IV neostigmine in Ogilvie syndrome, with prompt clinical and radiological response 4, 5. In a patient with Parkinson's disease specifically, neostigmine treatment caused rapid resolution of pseudo-obstruction 4.
Management Algorithm for This Patient
Immediate conservative measures:
- NPO status with nasogastric decompression
- Aggressive IV fluid resuscitation
- Correct electrolyte abnormalities (check potassium, magnesium, calcium)
- Discontinue anticholinergics and any opioid analgesics
- Mobilize patient if possible
Monitor cecal diameter closely:
- If >12 cm: proceed directly to neostigmine (do not wait 48 hours)
- If <12 cm: continue conservative therapy for up to 48 hours
Neostigmine administration (if indicated):
- Dose: 2 mg IV over 3-5 minutes
- Critical caveat: Requires cardiac monitoring due to bradycardia risk—particularly important in this patient with coronary artery disease
- Have atropine readily available
- Contraindicated if mechanical obstruction not definitively ruled out
If neostigmine fails or contraindicated:
- Colonoscopic decompression
- Surgical intervention only if perforation or ischemia develops
Important Clinical Pitfalls
- Do not assume complete obstruction is required for diagnosis—the presence of flatus/stool does not exclude Ogilvie syndrome
- Parkinson's disease is a known risk factor for colonic dysmotility due to alpha-synuclein deposition in the enteric nervous system 6
- Cardiac disease requires extra caution with neostigmine—this patient's coronary artery disease necessitates continuous cardiac monitoring during administration
- The 12 cm threshold is absolute—do not wait for conservative therapy to fail if cecal diameter exceeds this measurement